DOCSLIB.ORG

Novel Vaccine Safety Issues and Areas That Would Benefit from Further Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel Vaccine Safety Issues and Areas That Would Benefit from Further Research Analysis BMJ Glob Health: first published as 10.1136/bmjgh-2020-003814 on 19 May 2021. Downloaded from Novel vaccine safety issues and areas that would benefit from further research 1 2 3 4 Daniel A Salmon , Paul Henri Lambert, Hanna M Nohynek, Julianne Gee, Umesh D Parashar,5 Jacqueline E Tate,5 Annelies Wilder- Smith,6 7 8 9 Kenneth Y Hartigan- Go, Peter G Smith, Patrick Louis F Zuber To cite: Salmon DA, ABSTRACT Summary box Lambert PH, Nohynek HM, Vaccine licensure requires a very high safety standard et al. Novel vaccine safety and vaccines routinely used are very safe. Vaccine safety ► Adverse events following immunization that are rare, issues and areas that monitoring prelicensure and postlicensure enables would benefit from further happen in subpopulations, and have delayed onset continual assessment to ensure the benefits outweigh the research. BMJ Global Health are monitored post- licensure. risks and, when safety problems arise, they are quickly 2021;6:e003814. doi:10.1136/ ► Vaccine adverse reactions can be related to identified, characterised and further problems prevented bmjgh-2020-003814 genomics. when possible. We review five vaccine safety case studies: ► There are opportunities for additional research to (1) dengue vaccine and enhanced dengue disease, (2) Handling editor Seye Abimbola fully define the safety profile of vaccines. pandemic influenza vaccine and narcolepsy, (3) rotavirus ► Unanswered safety questions and real safety prob- vaccine and intussusception, (4) human papillomavirus Received 28 August 2020 lems can undermine public confidence in vaccines. Revised 1 December 2020 vaccine and postural orthostatic tachycardia syndrome and ► Transparent and timely communication about ad- Accepted 6 January 2021 complex regional pain syndrome, and (5) RTS,S/adjuvant verse events following immunization is crucial to system 01 malaria vaccine and meningitis, cerebral maintaining public trust. malaria, female mortality and rebound severe malaria. These case studies were selected because they are recent and varied in the vaccine safety challenges they elucidate. Bringing these case studies together, we develop lessons 2. Pandemic influenza vaccine and narcolep- learned that can be useful for addressing some of the sy. potential safety issues that will inevitably arise with new 3. Rotavirus vaccine and intussusception. vaccines. 4. Human papillomavirus (HPV) vaccine and postural orthostatic tachycardia syndrome http://gh.bmj.com/ (POTS) and complex regional pain syn- drome (CRPS). INTRODUCTION 5. RTS,S/AS01 malaria vaccine and meningi- tis, cerebral malaria, female mortality and Vaccines are held to a very high safety rebound severe malaria. standard as they are given to healthy individ- For each of these case studies, we review the on September 30, 2021 by guest. Protected copyright. uals to prevent rather than to treat disease, safety issues that have been identified, poten- often administered to a large proportion of tial biological mechanisms, epidemiological the population, and their use is supported by data, and finally, conclusions about causality governments and health authorities. Vaccines and areas for future research. These case routinely used are very safe and, while adverse studies were selected because they are recent reactions do occur, serious adverse reactions and varied in the vaccine safety challenges are very rare. Vaccine safety is monitored they elucidate. Bringing these case studies throughout the product life cycle—from together, we develop lessons learnt that can research and development through postlicen- be useful for addressing some of the potential © Author(s) (or their sure surveillance. This ensures that routinely safety issues that will inevitably arise with new employer(s)) 2021. Re- use used vaccines are very safe, the benefits permitted under CC BY-NC. No vaccines. commercial re- use. See rights outweigh the risks in the populations for and permissions. Published by which they are indicated and safety problems BMJ. if they arise are quickly identified, character- DENGUE VACCINE AND ENHANCED DENGUE For numbered affiliations see ised and further problems prevented when DISEASE end of article. possible. Dengue poses a significant public health Correspondence to In this paper, we review five vaccine safety problem in the tropics and subtropics with 1 Dr Daniel A Salmon; case studies (box 1): as many as 390 million infections annually. dsalmon1@ jhu. edu 1. Dengue vaccine and enhanced disease. After decades of research, the world’s first Salmon DA, et al. BMJ Global Health 2021;6:e003814. doi:10.1136/bmjgh-2020-003814 1 BMJ Global Health BMJ Glob Health: first published as 10.1136/bmjgh-2020-003814 on 19 May 2021. Downloaded from phase 3 clinical trial programme indicated that protec- Box 1 Summary of case study elements and key lessons tive efficacy varied according to serostatus prior to vacci- 4 Dengue vaccine and enhanced dengue disease nation and serotype. Vaccine- induced immunogenicity Dengvaxia was protective for seropositive vaccinees; seronegative was not predictive of protective clinical efficacy, and no vaccinees had an increased risk of hospitalisation and severe dengue. immune correlates (for protection or enhancing disease) Recommendations for vaccination only for dengue- seropositive were established.4 people. In the phase 3 trial, excess hospitalisations for dengue Key lessons: Need more understanding of impact of natural disease were observed among vaccine recipients 2–5 years of age. on vaccines. Precise risk estimates according to dengue serostatus Pandemic influenza vaccine and narcolepsy prior to vaccination could not be ascertained because Small but significant increase in narcolepsy following one adjuvanted of the limited numbers of samples collected at baseline. pandemic influenza vaccine. Pandemrix in Sweden, Finland, and UK A post hoc analysis of safety and efficacy used a novel (various rates, highest 1:16 000); the Sleep Apnoea Monitoring with Non-Invasive Applications study (1:18 400). dengue anti- non- structural protein 1 (NS1) IgG ELISA Key lessons: Postlicensure studies in large populations with different on samples from month 13 to retrospectively infer base- genetic backgrounds is important. Timing of vaccination during an line serostatus. These analyses showed that in seropositive outbreak may be important. trial participants aged 9–16 years, in the 66 months after Rotavirus vaccine and intussusception administration of the first vaccine dose, the vaccine was RotaShield was the first rotavirus vaccine on the market with protective. HRs, comparing vaccinated to placebo recip- intussusception rates of 1:10 000 (postlicensure). Concerns of higher ients, for hospitalised virologically confirmed dengue risk if given before 3 months led to age restriction; risk–benefit (VCD) and severe VCD, were 0.21 (95% CI 0.14 to 0.31) analysis led to discarding restriction. RotaShield was eventually pulled and 0.16 (95% CI 0.07 to 0.37), respectively. However, from market. in seronegative participants aged 9–16 years, vaccinees RotaTeq and Rotarix, next on the market, underwent large clinical had an increased risk of hospitalised and severe dengue, trials with intussusception rates 1-5:100 000 in high- income and with corresponding HRs of 1.41 (95% CI 0.74 to 2.68) middle- income countries; Rotarix showed no elevated risks in low- 5 income and middle- income country (no data from RotaTeq). and 2.44 (95% CI 0.47 to 12.56), respectively. A plau- Key lessons: Postlicensure studies in large populations are essential. sible hypothesis for these findings is that the vaccine acts Human papillomavirus vaccine and postural orthostatic as a ‘silent infection’, so that the first natural infection tachycardia syndrome and complex regional pain syndrome in seronegative recipients is then ‘secondary- like’, with Concerns over complex regional pain syndrome and postural an associated increased risk of severe disease, whereas orthostatic tachycardia syndrome following the human papillomavirus in seropositive recipients the first natural infection after vaccines on the market, Cervarix, Gardasil and Gardasil-9, led to lower vaccination is ‘tertiary- like’, which is not associated with a coverage, confidence and some loss of country recommendations. higher risk of severe disease.6 In December 2017, Global Vaccine adverse event reporting system, European Medical Agency, Advisory Committee on Vaccine Safety (GACVS) recom- Global Advisory Committee on Vaccine Safety and AAS and large-scale mended that Dengvaxia should only be administered to http://gh.bmj.com/ studies found no signals or patterns. individuals who had been previously infected with wild Key lessons: Postlicensure studies in large populations are essential 7 and effective communication about safety is vital dengue virus. Based on WHO’s Strategic Advisory Group RTS,S/adjuvant system 1 malaria vaccine and serious adverse of Experts (SAGE) recommendations, WHO’s posi- events tion published in 2018 is that for countries considering ► Exploratory analyses in phase 3 trial showed. Dengvaxia vaccination as part of their dengue control ► Meningitis: increase risk of meningitis in two trial sites in one age programme, a prevaccination screening strategy, in on September 30, 2021 by guest. Protected copyright. group; regarded as potential signal. which only dengue- seropositive persons are vaccinated, ► Cerebral malaria: increased in vaccinees versus controls. is recommended. 8 ► Mortality: increased mortality in vaccinated
Load more

Recommended publications
  • RTS,S Malaria Vaccine First Malaria Vaccine Will Be Piloted in Areas of Three African Countries Through Routine Immunization Programs
    CENTER FOR VACCINE INNOVATION AND ACCESS The RTS,S malaria vaccine First malaria vaccine will be piloted in areas of three African countries through routine immunization programs Summary the vaccine’s role in reducing childhood deaths and severe malaria, and its safety in the context of routine use. Data and Malaria kills more than 400,000 people a year worldwide and information from the MVIP will inform a WHO policy causes illness in tens of millions more, with most deaths recommendation on the broader use of the vaccine. RTS,S has occurring among young children living in sub-Saharan Africa. been approved for use in the pilot evaluation and Phase 4 Although existing interventions have helped to reduce malaria studies by the national regulatory authority in each of the three deaths significantly over the past 15 years, a vaccine could add participating countries. an important complementary tool for malaria control efforts. Financing for the MVIP has been mobilized through an RTS,S/AS01 (RTS,S) is the first malaria vaccine shown to unprecedented collaboration among three global health funding provide partial protection against malaria in young children. It bodies: Gavi, the Vaccine Alliance; the Global Fund to Fight will be the first malaria vaccine provided to young children AIDS, Tuberculosis and Malaria; and Unitaid. Additionally, through national immunization programs in three sub-Saharan WHO, PATH, and GSK are providing in-kind contributions, African countries—Ghana, Kenya, and Malawi. These countries which include GSK’s donation of the vaccine for use in the will introduce the vaccine in selected areas as part of a large- MVIP.
    [Show full text]
  • I Raise the Rates! April Edition
    I Raise the Rates! - April Edition I Raise the Rates! April Edition In this edition of I Raise the Rates (IRtR) you will find a variety of new resources from various public health partners, unique education opportunities, and a brief selection of popular media articles related to immunization. Updates from the American College of Physicians (ACP) Opportunity to Participate in ACP Quality Improvement Initiative to Increase Adult Influenza Immunization Rates APPLY NOW - Opportunity to participate in ACP's Quality Improvement Initiative to Increase Adult Influenza Immunization Rates. ACP is recruiting internal medicine and subspecialty practices and residency programs to participate in the I Raise the Rates quality improvement programs to increase influenza and adult immunization rates. ACP’s I Raise the Rates program, which is supported by funding from the CDC, Merck, and GSK, provides QI education and virtual coaching support from ACP Advance expert coaches to support increased adult immunization coverage. The program also offers access to a virtual learning community, tailored educational offerings, and the opportunity to earn more than 54 CME and ABIM MOC credits for program participants. Onboarding is underway so act now! Opportunity is limited, applicants will be considered on a first-come, first-served basis. Please see the attached recruitment flyer for more information about participation benefits and requirements as well as the application link. https://myemail.constantcontact.com/I-Raise-the-Rates----April-Edition---Layout-Template.html?soid=1124874283215&aid=uMyKdB7UvYQ 1/6 I Raise the Rates! - April Edition View the Flyer by Clicking Here ACP COVID-19 Vaccine Forum IV, Practical Clinical Considerations ACP COVID-19 Vaccine Forum IV, Practical Clinical Considerations was the forth in a series of vaccine forums hosted by ACP and Annals of Internal Medicine and was held on March 24, 2021.
    [Show full text]
  • Downloaded from Uniprotkb 667 (UP000005640.Fasta)
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.21.21260959; this version posted July 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Title page 2 Proteomic and metabolomic signatures associated with the immune response in 3 healthy individuals immunized with an inactivated SARS-CoV-2 vaccine 4 5 Yi Wang,1,#,* Xiaoxia Wang,2,# Laurence Don Wai Luu,3,# Shaojin Chen2, Fu Jin,1 6 Shufang Wang,4 Xiaolan Huang,1 Licheng Wang,2 Xiaocui Zhou,2 Xi Chen,2 Xiaodai 7 Cui,1 Jieqiong Li,5,* Jun Tai,6,* and Xiong Zhu2,* 8 9 1 Experimental Research Center, Capital Institute of Pediatrics, Beijing, 100020, P.R. 10 China 11 2 Central & Clinical Laboratory of Sanya People’s Hospital, Sanya, Hainan 572000, P. 12 R. China. 13 3 School of Biotechnology and Biomolecular Science, University of New South Wales, 14 Sydney, Australia 15 4 Nursing department of Sanya People’s Hospital, Sanya, Hainan 572000, P. R. China. 16 5 Department of Respiratory Disease, Beijing Pediatric Research Institute, Beijing 17 Children’s Hospital, Capital Medical University, National Center for Children’s 18 Health, Beijing 10045, P. R. China 19 6 Department of Otolaryngology, Head and Neck Surgery, Children's Hospital Capital 20 Institute of Pediatrics, Beijing 100020, P. R. China. 21 22 # These authors contributed equally 23 24 25 * Correspondence: 26 Dr.
    [Show full text]
  • HPV Vaccine Safety - Vaccine Safety
    CDC - HPV Vaccine Safety - Vaccine Safety Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options CDC Home CDC 24/7: Saving Lives. Protecting People.™ Search The CDC Vaccine Safety Vaccine Safety Vaccines Safety Basics Diphtheria, Tetanus, and Pertussis Vaccines: DTaP, Td, and Tdap Haemophilus Influenzae Type B (Hib) Hib Summary Human Papillomavirus (HPV) FAQs about HPV Vaccine Safety FAQ: Gardasil Vaccine recall JAMA Report Summary Information from FDA and CDC on Gardasil and its Safety (Archived) Measles, Mumps, Rubella (MMR) MMR Vaccine Safety Studies Measles, Mumps, Rubella, Varicella (MMRV) Information on the VSD MMRV Vaccine Safety Study MMRV Vaccine Safety Studies MMRV and Febrile Seizures Rotavirus Varicella Addressing Common Concerns Adjuvants Autism Vaccine not associated with autism CDC Statement: 2004 Pediatrics Paper CDC Statement on Pandemrix Fainting (Syncope) FAQs about Fainting (Syncope) After Vaccination Childhood Vaccines and Febrile Seizures Influenza Season 2012-2013 Influenza Season 2010-2011 GBS GBS and Menactra Meningococcal Vaccine FAQs about GBS and Menactra Meningococcal Vaccine IOM Assessment of Studies on Childhood Immunization Schedule IOM Report on Adverse Effects of Vaccines Pregnancy and Influenza Vaccine Safety Sudden Infant Death Syndrome (SIDS) Thimerosal http://www.cdc.gov/vaccinesafety/vaccines/HPV/index.html[10/13/2014 5:59:00 PM] CDC - HPV Vaccine Safety - Vaccine Safety CDC Study on Thimerosal and Risk of Autism
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • HHS Public Access Author Manuscript
    HHS Public Access Author manuscript Author Manuscript Author ManuscriptVaccine Author Manuscript. Author manuscript; Author Manuscript available in PMC 2016 January 27. Published in final edited form as: Vaccine. 2015 November 27; 33(48): 6865–6870. doi:10.1016/j.vaccine.2015.07.092. Catching-up with pentavalent vaccine: Exploring reasons behind lower rotavirus vaccine coverage in El Salvador✩ Eduardo Suarez-Castanedaa, Eleanor Burnettb,c, Miguel Elasa, Rafael Baltronsd, Lorenzo Pezzolie, Brendan Flanneryb, David Kleinbaumc, Lucia Helena de Oliveiraf, and M. Carolina Danovaro-Hollidayf,* aMinistry of Health, El Salvador bUS Centers for Disease Control and Prevention, Atlanta, GA, United States cEmory University, United States dPan American Health Organization, El Salvador eConsultant for the Pan American Health Organization, United States fPan American Health Organization, Washington, DC, United States Abstract Rotavirus vaccine was introduced in El Salvador in 2006 and is recommended to be given concomitantly with DTP–HepB–Haemophilus influenzae type b (pentavalent) vaccine at ages 2 months (upper age limit 15 weeks) and 4 months (upper age limit 8 months) of age. However, rotavirus vaccination coverage continues to lag behind that of pentavalent vaccine, even in years when national rotavirus vaccine stockouts have not occurred. We analyzed factors associated with receipt of oral rotavirus vaccine among children who received at least 2 doses of pentavalent vaccine in a stratified cluster survey of children aged 24–59 months conducted in El Salvador in 2011. Vaccine doses included were documented on vaccination cards (94.4%) or in health facility records (5.6%). Logistic regression and survival analysis were used to assess factors associated with vaccination status and age at vaccination.
    [Show full text]
  • COVID-19 and Cancer: from Basic Mechanisms to Vaccine Development Using Nanotechnology
    International Immunopharmacology 90 (2021) 107247 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology Hyun Jee Han a,*, Chinekwu Nwagwu b, Obumneme Anyim c, Chinedu Ekweremadu d, San Kim e a University College London, Department of Neonatology, United Kingdom b Department of Pharmaceutics, University of Nigeria Nsukka, Nigeria c Department of Internal Medicine, University of Nigeria Teaching Hospital Ituku-Ozalla, Enugu, Nigeria d Department of Pharmaceutics and Pharmaceutical Technology Enugu State University of Science and Technology, Nigeria e Basildon and Thurrock University Hospital, United Kingdom ARTICLE INFO ABSTRACT Keywords: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV- COVID-19 2), is a global pandemic which has induced unprecedented ramifications,severely affecting our society due to the Cancer long incubation time, unpredictably high prevalence and lack of effective vaccines. One of the interesting notions Vaccine development is that there is an association between COVID-19 and cancer. Cancer patients seem to exhibit exacerbated Pharmaceutics conditions and a higher mortality rate when exposed to the virus. Therefore, vaccines are the promising solution Nanotechnology to minimise the problem amongst cancer patients threatened by the new viral strains. However, there are still limitations to be considered, including the efficacy of COVID vaccines for immunocompromised individuals, possible interactions between the vaccine and cancer, and personalised medicine. Not only to eradicate the pandemic, but also to make it more effective for immunocompromised patients who are suffering from cancer, a successful vaccine platform is required through the implementation of nanotechnology which can also enable scalable manufacturing and worldwide distribution along with its faster and precise delivery.
    [Show full text]
  • Vaccines for Preteens
    | DISEASES and the VACCINES THAT PREVENT THEM | INFORMATION FOR PARENTS Vaccines for Preteens: What Parents Should Know Last updated JANUARY 2017 Why does my child need vaccines now? to get vaccinated. The best time to get the flu vaccine is as soon as it’s available in your community, ideally by October. Vaccines aren’t just for babies. Some of the vaccines that While it’s best to be vaccinated before flu begins causing babies get can wear off as kids get older. And as kids grow up illness in your community, flu vaccination can be beneficial as they may come in contact with different diseases than when long as flu viruses are circulating, even in January or later. they were babies. There are vaccines that can help protect your preteen or teen from these other illnesses. When should my child be vaccinated? What vaccines does my child need? A good time to get these vaccines is during a yearly health Tdap Vaccine checkup. Your preteen or teen can also get these vaccines at This vaccine helps protect against three serious diseases: a physical exam required for sports, school, or camp. It’s a tetanus, diphtheria, and pertussis (whooping cough). good idea to ask the doctor or nurse every year if there are any Preteens should get Tdap at age 11 or 12. If your teen didn’t vaccines that your child may need. get a Tdap shot as a preteen, ask their doctor or nurse about getting the shot now. What else should I know about these vaccines? These vaccines have all been studied very carefully and are Meningococcal Vaccine safe.
    [Show full text]
  • Takeda Vaccines Innovation for Global Impact
    TAKEDA VACCINES INNOVATION FOR GLOBAL IMPACT CHOO BENG GOH, MD Regional Lead for Medical Affairs Asia, Global Vaccine Business Unit OUR MISSION Develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world 2 WE HAVE BUILT A GLOBAL VACCINE BUSINESS UPON A STRONG FOUNDATION IN JAPAN Global pivotal Phase 3 PARTNERSHIPS clinical trial of dengue ACQUISITIONS Polio vaccine vaccine candidate initiated: candidate Japan vaccine business Global vaccine business Dengue vaccine 20,100 participants in 8 Bill & Melinda Gates Foundation established established candidate countries in 2 regions Norovirus vaccine Zika vaccine candidate 1946 2012 candidate 2016 U.S. Government‐ BARDA 1947 2010 2014 2018 1st Takeda Multiple vaccine products Partnered with Japan Phase 3 clinical trial results of manufactured vaccine manufactured internally government to develop and dengue vaccine candidate is and marketed in Japan supply pandemic influenza expected in H2 FY18 vaccines for people in Japan 3 THE VACCINE MARKET IS AN ATTRACTIVE PLACE FOR INVESTMENT Vaccine sales growth projected at 7.1% between Durability in sales with limited impact 2017 and 2024, reaching $44.6 billions in 20241 of patent expiry Blockbuster potential in newly launched vaccines Threat of emerging and existing infectious diseases with epidemic potential 1 Evaluate Pharma report 2018 4 OUR STRATEGY Develop vaccines with global BUILD A GLOBAL TACKLE Target the greatest opportunity relevance and business potential PIPELINE
    [Show full text]
  • Candidate Rotavirus Vaccine Recommendations for Consideration by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization
    Candidate rotavirus vaccine recommendations for consideration by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization 1. Overall recommendation WHO strongly recommends the inclusion of rotavirus vaccination into the national immunization programmes of all regions of the world. In particular, countries where deaths among children due to diarrhoeal diseases account for ≥10% of under-5 mortality rate should prioritize the introduction of rotavirus vaccination. Countries where deaths among children due to diarrhoeal diseases account for <10% of under-5 mortality rate should also consider the introduction of rotavirus vaccination based on anticipated reduction in mortality and morbidity from diarrhoea, savings in health care costs, and the cost-effectiveness of vaccination. Justification: Rotavirus is a major cause of mortality in countries with high diarrhoeal disease mortality among children under five years of age. Every year, rotavirus gastroenteritis is estimated to cause approximately 527,000 (475,000-580,000) deaths globally among children <5 years old. Most of these deaths occur in developing countries and 90% of the rotavirus- associated fatalities occur in Africa and Asia alone. Globally, >2 million children are hospitalized each year for rotavirus infections. In a recent report of sentinel hospital-based rotavirus surveillance from 35 nations representing each of the six WHO regions between 2001 and 2008, an average of 40% (range= 34%-45%) of hospitalizations for diarrhea among children < 5 years old were attributable to rotavirus infection. 2. Detailed recommendation: Extrapolating efficacy data from a rotavirus vaccine study performed in one population to use of same rotavirus vaccine in other populations Efficacy/effectiveness data from a rotavirus vaccine study performed in a population from one of three under-5 mortality rate categories* can be extrapolated for use in populations in the same under-5 mortality rate category.
    [Show full text]
  • Rotavirus Vaccine: Questions and Answers for Health Care Providers
    Rotavirus Vaccine Questions and Answers for Health Care Providers In April 2014, Manitoba Health, Seniors and Active Living launched a publicly-funded Rotavirus Immunization Program for infants born on or after March 1, 2014. In 2018, Manitoba, along with the rest of Canada, switched from RotarixTM to RotaTeq®. As of May 15, 2021, Manitoba has switched back to Rotarix®, for use in its publicly-funded Rotavirus Immunization Program, for infants born on or after April 1, 2021. This document includes an updated list of questions and answers for your reference. 1. Why is there a Rotavirus Immunization Program in Manitoba? 2. Who qualifies for publicly-funded rotavirus vaccine? 3. Which rotavirus vaccine does Manitoba use? 4. Why does the vaccine series need to be completed before eight months of age? 5. How is Rotarix® packaged? 6. How are the oral tube and cap disposed of after use? 7. Should a spit-up dose of vaccine be repeated? 8. Are there any precautions that health care providers should take when administering the oral rotavirus vaccine? 9. Oral rotavirus vaccine contains sucrose in an amount expected to have an effect on immunization injection pain. When should Rotarix® be given in relation to other vaccines to elicit a reduction in pain? 10. How do I administer Rotarix®? 11. Is additional screening for potential contraindications required prior to administering rotavirus vaccine? 12. Can infants born to mothers on immunosuppressive medication be immunized? 13. Are there any issues related to circulating maternal antibodies interfering with the response to the live attenuated vaccine? 14. Are the two rotavirus vaccines, RotaTeq® and Rotarix™, interchangeable? 15.
    [Show full text]
  • Considerations for Causality Assessment of Neurological And
    Occasional essay J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2021-326924 on 6 August 2021. Downloaded from Considerations for causality assessment of neurological and neuropsychiatric complications of SARS- CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder Matt Butler ,1 Arina Tamborska,2,3 Greta K Wood,2,3 Mark Ellul,4 Rhys H Thomas,5,6 Ian Galea ,7 Sarah Pett,8 Bhagteshwar Singh,3 Tom Solomon,4 Thomas Arthur Pollak,9 Benedict D Michael,2,3 Timothy R Nicholson10 For numbered affiliations see INTRODUCTION More severe potential adverse effects in the open- end of article. The scientific community rapidly responded to label phase of vaccine roll- outs are being collected the COVID-19 pandemic by developing novel through national surveillance systems. In the USA, Correspondence to SARS- CoV-2 vaccines (table 1). As of early June Dr Timothy R Nicholson, King’s roughly 372 adverse events have been reported per College London, London WC2R 2021, an estimated 2 billion doses have been million doses, which is a lower rate than expected 1 2LS, UK; timothy. nicholson@ administered worldwide. Neurological adverse based on the clinical trials.6 kcl. ac. uk events following immunisation (AEFI), such as In the UK, adverse events are reported via the cerebral venous sinus thrombosis and demyelin- MB and AT are joint first Coronavirus Yellow Card reporting website. As of ating episodes, have been reported. In some coun- authors. early June 2021, approximately 250 000 Yellow tries, these have led to the temporary halting of BDM and TRN are joint senior Cards have been submitted, equating to around authors.
    [Show full text]